CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

Neurology. 2005 Apr 12;64(7):1294-7. doi: 10.1212/01.WNL.0000156914.16988.56.

Abstract

Baseline CSF amyloid beta-peptide-42 (Abeta42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of Abeta42 and P-tau.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Biomarkers / cerebrospinal fluid
  • Brain / metabolism*
  • Brain / pathology
  • Brain / physiopathology
  • Cognition Disorders / cerebrospinal fluid*
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / physiopathology
  • Cohort Studies
  • Dementia / cerebrospinal fluid*
  • Dementia / diagnosis*
  • Dementia / physiopathology
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neurofibrillary Tangles / metabolism
  • Neurofibrillary Tangles / pathology
  • Peptide Fragments / cerebrospinal fluid*
  • Phosphorylation
  • Plaque, Amyloid / metabolism
  • Plaque, Amyloid / pathology
  • Predictive Value of Tests
  • tau Proteins / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins